Additional Information
Book Details
Abstract
This issue of Hematology/Oncology Clinics is focused on Hodgkin's Lymphoma and covers such topics as First HRS-cell line L428 and the detection of the CD-30 Antigen , “Normal“ CD30-B-lymphocytes, CD-30-Antigen, Combination-Chemo-Radiotherapy, Early intensification (escBEACOPP), Customized/Targeted Therapy, and more.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Hodgkin Lymphoma\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Hematology/Oncology Clinics Of North America \r | viii | ||
| Preface | ix | ||
| First Hodgkin Cell Line L428 and the CD30 Antigen | 1 | ||
| Key points | 1 | ||
| Why was it essential to establish a Hodgkin cell line? | 1 | ||
| The establishment of the L428 cell line | 1 | ||
| Features of the L428 Hodgkin Cell Line | 2 | ||
| Discovery of the CD30 antigen and its application in research, diagnostic, and therapy | 4 | ||
| Detection of HRS-cell-related Antigens by Rabbit Polyclonal Antisera | 4 | ||
| Detection of the Proliferation-Associated Antigen Ki-67 and the HRS-cell-Related Antigen Ki-1 | 4 | ||
| Ki-1 by the monoclonal antibody approach | 4 | ||
| CD30 as a Diagnostic Target: Identification of a New Lymphoma Entity and Its Detection in Formol-fixed and Paraffin-embedde ... | 4 | ||
| Biosynthesis and Structure of CD30 and Shedding as a Soluble Form | 5 | ||
| Derivation and Molecular Characteristics of HRS Cells | 6 | ||
| Hodgkin Lymphoma Includes 2 Different Entities | 7 | ||
| CD30 as a Therapeutic Target | 7 | ||
| Studies with naked anti-CD30 antibodies and the first anti-CD30-drug conjugate | 7 | ||
| Breakthrough in CD30-targeted antibody therapy | 8 | ||
| References | 9 | ||
| Advancing Antibody Drug Conjugation | 13 | ||
| Key points | 13 | ||
| The CD30 target antigen | 14 | ||
| Development of the drug-linker component for a targeted anti-CD30 therapeutic | 15 | ||
| Evaluation of brentuximab vedotin activity in vitro | 18 | ||
| Evaluation of brentuximab vedotin activity in vivo | 20 | ||
| Clinical experience with brentuximab vedotin | 20 | ||
| References | 22 | ||
| Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma | 27 | ||
| Key points | 27 | ||
| Introduction | 27 | ||
| Phase I studies | 28 | ||
| Pivotal phase II study | 28 | ||
| Brentuximab vedotin in relapsed pretransplant and transplant-ineligible patients with Hodgkin lymphoma | 29 | ||
| Experience with brentuximab vedotin in patients undergoing allogeneic stem cell transplantation | 29 | ||
| Brentuximab vedotin in front-line regimens | 30 | ||
| Summary | 30 | ||
| References | 31 | ||
| Combination Chemoradiotherapy in Early Hodgkin Lymphoma | 33 | ||
| Key points | 33 | ||
| Introduction | 33 | ||
| Decades of Successes | 33 | ||
| Background | 34 | ||
| Treatment | 34 | ||
| RT alone is not an option | 34 | ||
| SCs and Late Toxicities | 35 | ||
| Evaluating the late impact of our treatments | 35 | ||
| Caveats in interpreting clinical trials for localized HL | 37 | ||
| Absence of Evidence is Not Always Evidence of Absence | 37 | ||
| Reducing RT | 38 | ||
| Trying to Reduce Side Effects | 38 | ||
| Reducing the size of the RT field | 38 | ||
| Dosimetric model | 38 | ||
| Retrospective study | 38 | ||
| Randomized trials | 38 | ||
| HD8 | 38 | ||
| H8-U | 39 | ||
| Milan | 39 | ||
| HD94 | 39 | ||
| Reducing the dose of RT | 39 | ||
| The HD10 trial | 39 | ||
| The H9F trial | 39 | ||
| CT alone | 40 | ||
| The Ultimate Reduction of Radiotherapy | 40 | ||
| Interim FDG-PET scan | 41 | ||
| Tailoring the Treatment? | 41 | ||
| Introduction | 41 | ||
| Interim FDG-PET | 42 | ||
| Clinical studies | 42 | ||
| RAPID trial | 42 | ||
| H10 trial | 43 | ||
| iPET conclusion | 44 | ||
| Summary | 44 | ||
| Not One Size Fits All | 44 | ||
| References | 44 | ||
| Balancing Risks and Benefits of Therapy for Patients with Favorable-Risk Limited-Stage Hodgkin Lymphoma | 49 | ||
| Key points | 49 | ||
| Introduction | 49 | ||
| Patient population and current guidelines | 51 | ||
| Components of the decision-making process | 52 | ||
| Outcome Measures and Surrogates | 52 | ||
| Therapy that Includes Radiation | 53 | ||
| Therapy with Chemotherapy Alone | 54 | ||
| The present and future | 58 | ||
| References | 60 | ||
| Early Intensification Treatment Approach in Advanced-stage Hodgkin Lymphoma | 65 | ||
| Key points | 65 | ||
| Introduction | 65 | ||
| Efficacy: PFS and OS | 66 | ||
| HD9 | 66 | ||
| HD12 | 66 | ||
| HD15 | 66 | ||
| HD18 | 67 | ||
| Acute and long-term toxicities | 67 | ||
| Acute Toxicity | 67 | ||
| Leukopenia | 67 | ||
| Gonadal Toxicity | 68 | ||
| Long-Term Toxicity | 68 | ||
| Challenges in the treatment of older patients with intensified regimens | 69 | ||
| Early or late intensification? Pros and cons | 69 | ||
| References | 72 | ||
| Induction Therapy for Advanced-stage Hodgkin Lymphoma | 75 | ||
| Key points | 75 | ||
| Introduction: nature of the problem | 75 | ||
| Clinical outcomes | 77 | ||
| Overall Results with ABVD Chemotherapy | 77 | ||
| Results with ABVD Compared with More Dose-intense Initial Therapy | 77 | ||
| Results with Subsequent Salvage Chemotherapy After Initial ABVD Chemotherapy | 79 | ||
| Complications and concerns | 79 | ||
| Acute Toxicity | 79 | ||
| Hematologic toxicity | 79 | ||
| Infection | 80 | ||
| Treatment-related mortality | 80 | ||
| Long-Term Toxicity | 81 | ||
| Leukemia risk | 81 | ||
| Infertility | 81 | ||
| Stem cell injury | 82 | ||
| Cardiac toxicity | 82 | ||
| Pulmonary toxicity | 82 | ||
| Toxicity in the elderly | 82 | ||
| Summary | 83 | ||
| References | 84 | ||
| FDG-PET Response–adapted Therapy | 87 | ||
| Key points | 87 | ||
| Introduction | 87 | ||
| The Hodgkin Lymphoma Therapeutic Dilemma | 87 | ||
| Fluorodeoxyglucose Positron Emission Tomography in HL | 88 | ||
| Early treatment monitoring with FDG-PET | 89 | ||
| PET response–adapted HL therapy: early-stage disease | 90 | ||
| PET response–adapted HL therapy: advanced-stage disease | 94 | ||
| Completed Trials | 94 | ||
| Ongoing Trials | 94 | ||
| The importance of interpretation criteria | 96 | ||
| Postchemotherapy FDG-PET/CT for selection of patients for consolidation radiotherapy | 96 | ||
| PET/CT before high-dose salvage therapy in relapsed HL | 97 | ||
| PET/CT in patients who relapsed after second-line therapy | 98 | ||
| Summary | 98 | ||
| References | 98 | ||
| Customized Targeted Therapy in Hodgkin Lymphoma | 105 | ||
| Key points | 105 | ||
| Introduction | 105 | ||
| Emerging targets in the biology of HL | 106 | ||
| Targeting molecules expressed on HRS cell surface | 107 | ||
| Targeting CD30 | 107 | ||
| Other Cell Surface Targets | 112 | ||
| Targeting the tumor microenvironment | 113 | ||
| Adoptive immunotherapy in HL | 114 | ||
| Targeting downstream signaling and intracellular survival pathways | 115 | ||
| Summary | 116 | ||
| References | 117 | ||
| Relapsed/Refractory Hodgkin Lymphoma | 123 | ||
| Key points | 123 | ||
| Introduction | 123 | ||
| Salvage therapy and HDCT/ASCT | 124 | ||
| Which Prognostic Factors at Progression/Relapse Are Important? | 124 | ||
| Which Salvage Regimen? | 124 | ||
| Why Give HDCT and ASCT? | 126 | ||
| Are There Differences Between Preparative Regimens for ASCT? | 127 | ||
| Why Evaluate Response to Salvage Using FDG-PET Pre-ASCT? | 127 | ||
| Can Results of ASCT Be Improved by Sequential HDCT or Tandem ASCT? | 128 | ||
| SHDCT | 129 | ||
| Tandem ASCT | 129 | ||
| Can Results of ASCT Be Improved by Incorporating Novel Agents? | 130 | ||
| What is the Prognosis for Patients Who Relapse Post-ASCT? | 130 | ||
| Do we need RIC-alloSCT for RR-HL? | 131 | ||
| What About Myeloablative Allogeneic SCT? | 131 | ||
| What Is the Advantage of RIC-alloSCT Compared to MAC? | 131 | ||
| Which Retrospective Studies of RIC-AlloSCT Are Informative? | 131 | ||
| Are There Prospective Studies of RIC-alloSCT? | 134 | ||
| What Prognostic Factors Before RIC-alloSCT Are Important? | 135 | ||
| Does Donor Type Matter? | 135 | ||
| Are Differences Between RIC-alloSCT Preparative Regimens Relevant? | 136 | ||
| Is There Evidence For a GVL Effect? | 136 | ||
| Are Donor Lymphocyte Infusions Effective? | 136 | ||
| Can We Incorporate Alternative Strategies Into the RIC-alloSCT Approach? | 137 | ||
| PET-adapted approaches | 137 | ||
| Novel agents | 137 | ||
| A treatment algorithm for RR-HL | 138 | ||
| References | 139 | ||
| Index | 149 |